Health Care · Surgical & Medical Instruments & Apparatus

SKIN Beauty Health Co SEC Filings & Insider Trading Activity 2026

company
CIK 181809368 filings
Russell 2000

SKIN at a glance

Beauty Health Co (SKIN, SEC CIK 1818093) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Beauty Health Co (SKIN) reported revenue of $300.8 million (down 10.0% from FY2024) and a net loss of $9.5 million. Diluted EPS was -$0.16.
  • As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding Beauty Health Co (SKIN) shares worth $12.1 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$300.8M
−10.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
19 funds
$12.1M · −4 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $69.2M, down 2.1% YoY from $70.7M
  • Gross margin 68.2% vs 64.6% YoY, operating margin 7.2% vs (8.8)%
  • Best line Consumables: $50.4M, up 1.2%; weakest Delivery Systems: $18.8M, down 9.9%
  • Cash, equivalents and restricted cash $112.4M; nine-month operating cash flow $8.4M vs $22.3M
  • Headwinds: macroeconomic and credit conditions, tariffs, geopolitical risks, and $250.0M 2028 Notes requiring refinancing or additional capital

Risk Factors

  • Newly added rebranding risk: April 22, 2026 name change may increase marketing costs and weaken customer recognition
  • Nasdaq compliance risk: $1.00 bid-price deficiency resolved after October 14, 2026 1-for-20 reverse split
  • Delisting risk: another failure within one year could trigger Staff Delisting Determination without a compliance period
  • Debt liquidity risk: $250.0 million 2028 Notes exceeded $112.4 million cash, equivalents and restricted cash at September 30, 2026
  • Capital markets risk: delisting could trigger 2028 Notes repurchase at principal plus accrued interest

AI summary of the SKIN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal quarter ended September 30, 2026 results announced November 5, 2026
  • Investor conference call scheduled to discuss quarterly financial performance

Item EX-99.1: Item EX-99.1

  • Q3 revenue $69.2M, down 2.1%, as delivery-system sales fell to $18.8M from $20.8M
  • Consumables returned to growth, reaching $50.4M versus $49.8M, supporting the 37,342-system active install base
Filed Oct 14, 2026Full analysis →

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • 1-for-20 reverse split effective October 14, 2026, reducing shares outstanding while proportionally increasing per-share price
  • Nasdaq Capital Market trading continues under ticker SKIN, with new CUSIP 88331L306

Item EX-99.1: Item EX-99.1

  • 1-for-20 reverse split effective October 14, 2026, with split-adjusted Nasdaq trading under SKIN and new CUSIP 88331L306
  • Shares outstanding expected to decline from approximately 130.3 million to 6.5 million, without changing ownership percentages

Item 7.01: Regulation FD Disclosure

  • Reverse stock split effective October 14, 2026 at 12:00 a.m. Eastern Time
  • Shareholders should expect adjusted share counts and per-share metrics following the split

Item 3.03: Material Modification to Rights of Security Holders

  • Item 3.03 points investors to the reverse stock split disclosure under Item 5.03
  • Reverse stock split represents a material change to shareholders’ ownership structure and per-share economics
Filed Oct 6, 2026Full analysis →

Item 1.02: Termination of a Material Definitive Agreement

  • $0 remaining 1.25% convertible senior notes due 2026 after full repayment on September 30, 2026
  • Accrued and unpaid interest paid alongside principal, eliminating the associated debt obligation

Item 7.01: Regulation FD Disclosure

  • Notes fully retired on September 30, 2026, one day before scheduled October 1 maturity
  • $103.235M principal repayment, plus $645,218.75 accrued interest

AI summaries of SKIN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SKIN

Don't miss the next SKIN filing

  • Alerts as it files. A push when SKIN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SKIN, by share count.
  • Ask anything. An AI agent that reads every SKIN filing and answers with sources.

SKIN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Malha Pedro Bruno FerreiraFOct 9, 2026$0.55
Malha Pedro Bruno FerreiraFOct 9, 2026$0.55
MONAHAN MICHAEL P.FAug 10, 2026$0.64
Lewis SheriFApr 9, 2026$0.92
MONAHAN MICHAEL P.FApr 9, 2026$0.92
Lewis SheriAMar 20, 2026-
Menezes RonaldAMar 20, 2026-
MONAHAN MICHAEL P.AMar 20, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$334.3M$300.8M
Gross Profit-$182.3M$196.4M
Operating Income--$67.8M-$20.8M
Net Income--$29.1M-$9.5M
Gross Margin-54.5%65.3%
Op. Margin--20.3%-6.9%
Net Margin--8.7%-3.2%
Balance Sheet
Total Assets$929.1M$685.7M$499.8M
Equity-$51.8M$61.1M
ROE--56.2%-15.6%
Per Share
EPS-$-0.36$-0.16
Cash Flow
Operating CF-$16.1M$37.5M
CapEx$3.8M$756K$303K

Source: XBRL data in Beauty Health Co (SKIN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SKIN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SKIN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202619$12.1M
Q2 202623$23.1M
Q1 202626$37.8M
Q4 202524$61.2M
Q3 202525$81.3M
Q2 202525$76.8M
Q1 202523$42.5M
Q4 202418$50.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SKIN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 14, 2026Analysis-
4Oct 13, 2026--
8-KOct 6, 2026Analysis-
8-KSep 28, 2026Analysis-
8-KSep 10, 2026Analysis-
8-KAug 14, 2026Analysis-
4Aug 12, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
SC 13GJul 17, 2026-
8-KJun 22, 2026Analysis-
8-KJun 16, 2026Analysis-
8-KMay 12, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
8-KMay 6, 2026Analysis
8-KApr 22, 2026--
SC 13GApr 20, 2026-
4Apr 13, 2026--
4Apr 13, 2026--
4Mar 24, 2026--
4Mar 24, 2026--
4Mar 24, 2026--

Related Health Care companies

All Health Care →

SKIN SEC filings: frequently asked questions

Which institutions hold SKIN stock?

As of September 30, 2026, the largest Beauty Health Co (SKIN) holders among the 13F filers tracked by SignalX were BlackRock ($5.3 million), Millennium Management ($3.2 million), Vanguard Capital Management LLC ($2.2 million), D.E. Shaw & Co ($413,000), Renaissance Technologies LLC ($279,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SKIN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Beauty Health Co (SKIN) reported revenue of $300.8 million (down 10.0% from FY2024) and a net loss of $9.5 million. Diluted EPS was -$0.16. The figures come from the XBRL data in the 10-K.

What did SKIN report in its latest 8-K?

Beauty Health Co (SKIN) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended September 30, 2026 results announced November 5, 2026.

What are the latest SKIN SEC filings?

Beauty Health Co (SKIN) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 13, 2026.

What is SKIN's SEC CIK number?

Beauty Health Co (SKIN)'s SEC Central Index Key (CIK) is 1818093. EDGAR lists every SKIN filing under that number.

Ask anything about SKIN

The research agent reads SKIN's filings, financials, insider trades and 13F holders, then answers with sources.